Charles River Laboratories International Inc., which provices drug-research services, gave 2013 earnings guidance that was below Wall Street’s expectations. In addition, the Wilmington company now expects its 2012 per-share earnings to come in between the low end and the midpoint of its previously estimated range of $2.68 to $2.73. The company expects sales to grow by 3 to 5 percent next year, and that non-GAAP earnings per share would be in the range of $2.80 to $2.90. The analyst consensus for 2013 is $3.02, RTTNews reported.
Charles River’s 2013 forecast disappoints
December 13, 2012
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢